FIELD: medicine.
SUBSTANCE: engineered recombinant protein molecule for preparing a recombinant vaccine for an infection caused by swine influenza virus (HlNlv-2009). The molecule consists of a residue of methionine, a sequence of extracellular M2 protein domain of 2 to 24 amino acids and a sequence of a nuclear hepatitis B virus antigen of 4 to 149 amino acids. The molecule is able to form virus-like particles. There are also disclosed a recombinant nucleic acid coding such molecule, a vector for its expression, virus-like particles formed by such molecules and a vaccine based on the prepared virus-like particles.
EFFECT: prepared vaccine can be considered as a candidate recombinant swine influenza virus vaccine.
6 cl, 8 dwg, 3 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CROSS-REACTIVE RECOMBINANT HUMAN INFLUENZA A VIRUS VACCINE | 2020 |
|
RU2742336C1 |
| RECOMBINANT ANTI-INFLUENZA VACCINE WITH WIDE RANGE OF PROTECTION AND METHOD FOR ITS PREPARATION | 2017 |
|
RU2757013C2 |
| UNIVERSAL AVIAN INFLUENZA VIRUS VACCINE | 2007 |
|
RU2358981C2 |
| UNIVERSAL ANTI-INFECTIOUS VACCINE | 2015 |
|
RU2618918C2 |
| RECOMBINANT VIRAL VECTOR AND EXPRESSION SYSTEM IN PLANT CELLS OF HYBRID PROTEIN CONTAINING EXTRACELLULAR DOMAIN OF PROTEIN M2 OF INFLUENZA VIRUS ATTACHED TO CORE ANTIGEN OF HEPATITIS B VIRUS | 2010 |
|
RU2460796C2 |
| BROAD-SPECTRUM M2 PROTEIN ECTODOMAIN AVIAN INFLUENZA TYPE A VACCINE | 2014 |
|
RU2571944C1 |
| CASSETTE INTENDED FOR OBTAINING PLASMID VECTORS USED TO CREATE CELL PRODUCERS OF VIRUS-LIKE PARTICLES (VLP) OF INFLUENZA VIRUS | 2018 |
|
RU2680703C1 |
| ATTENUATED GRIPPOSE VECTOR AND MUCOSAL UNIVERSAL GRIPPOSE VACCINE ON ITS BASIS | 2016 |
|
RU2660562C2 |
| FLU VIRUS PROTEINS PRODUCER MDCK CELL (OPTIONS) | 2018 |
|
RU2681482C1 |
| LENTIVIRUS PLASMIDA (OPTIONS), METHOD FOR ITS OBTAINING (OPTIONS), SET OF PRIMERS FOR OBTAINING LENTIVIRUS PLASMID VECTOR (OPTIONS) | 2018 |
|
RU2680537C1 |
